Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Akoya Biosciences Q4 2023 GAAP EPS $(0.22) Beats $(0.28) Estimate, Sales $26.49M Beat $25.89M Estimate

Author: Benzinga Newsdesk | March 04, 2024 05:15pm
Akoya Biosciences (NASDAQ:AKYA) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.28) by 21.43 percent. The company reported quarterly sales of $26.49 million which beat the analyst consensus estimate of $25.89 million by 2.31 percent. This is a 24.83 percent increase over sales of $21.22 million the same period last year.

Posted In: AKYA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist